CA2668292C - Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor - Google Patents

Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor Download PDF

Info

Publication number
CA2668292C
CA2668292C CA2668292A CA2668292A CA2668292C CA 2668292 C CA2668292 C CA 2668292C CA 2668292 A CA2668292 A CA 2668292A CA 2668292 A CA2668292 A CA 2668292A CA 2668292 C CA2668292 C CA 2668292C
Authority
CA
Canada
Prior art keywords
csf
functional homologue
sequence identity
seq
pneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2668292A
Other languages
English (en)
French (fr)
Other versions
CA2668292A1 (en
Inventor
Kaare Fiala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure AS filed Critical Drugrecure AS
Publication of CA2668292A1 publication Critical patent/CA2668292A1/en
Application granted granted Critical
Publication of CA2668292C publication Critical patent/CA2668292C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2668292A 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor Active CA2668292C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86419006P 2006-11-03 2006-11-03
US60/864,190 2006-11-03
US94751107P 2007-07-02 2007-07-02
US60/947,511 2007-07-02
PCT/DK2007/050161 WO2008052567A2 (en) 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor

Publications (2)

Publication Number Publication Date
CA2668292A1 CA2668292A1 (en) 2008-05-08
CA2668292C true CA2668292C (en) 2018-04-03

Family

ID=39344625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2668292A Active CA2668292C (en) 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor

Country Status (8)

Country Link
US (1) US20100015217A1 (enExample)
EP (1) EP2094290B1 (enExample)
JP (3) JP2010508365A (enExample)
AU (1) AU2007315402B2 (enExample)
BR (1) BRPI0717958B8 (enExample)
CA (1) CA2668292C (enExample)
MX (1) MX2009004802A (enExample)
WO (1) WO2008052567A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
US9161969B2 (en) 2011-03-22 2015-10-20 Board Of Regents, The University Of Texas System Protection against influenza infection by granulocyte-macrophage colony stimulating factor
US9855316B2 (en) 2011-04-07 2018-01-02 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction
EP2850176B1 (en) * 2012-05-18 2019-01-16 Syracuse University Controlling pseudomonas aeruginosa persister cells with gm-csf
WO2014012559A1 (en) * 2012-07-20 2014-01-23 Trifoilium Aps Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
WO2014096032A1 (en) * 2012-12-18 2014-06-26 Trifoilium Aps Gm-csf for treatment of chronic sinusitis
EP2958582A1 (en) 2013-02-20 2015-12-30 Trifoilium ApS Gm-csf for treatment of chronic oral mucositis
WO2015110536A1 (en) * 2014-01-22 2015-07-30 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
EP3113789A1 (en) 2014-03-07 2017-01-11 Reponex Pharmaceuticals APS Compositions for treating lung infections by airway administration
JP2017524655A (ja) * 2014-05-23 2017-08-31 レポネックス・ファーマシューティカルズ・エーピーエス 創傷の治癒を促進するための組成物
WO2016012608A1 (en) 2014-07-24 2016-01-28 Reponex Pharmaceuticals Aps Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
EP3697432A1 (en) * 2017-10-16 2020-08-26 Drugrecure ApS Gm-csf for treating refractory non-tuberculous mycobacteria infections
EP4121095A4 (en) * 2020-03-20 2024-04-03 The Regents of the University of Colorado, a body corporate METHODS AND COMPOSITIONS FOR TREATING VIRUS DISEASES WITH GRANULOCYTE MACROPHAGE COLONIA STIMULATING FACTOR (GM-CSF)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US9269067B2 (en) * 2002-04-04 2016-02-23 Altisource Solutions S.À.R.L. Method and apparatus for providing selective access to information
US7512585B2 (en) 2002-07-11 2009-03-31 Oracle International Corporation Support for multiple mechanisms for accessing data stores

Also Published As

Publication number Publication date
WO2008052567A2 (en) 2008-05-08
EP2094290B1 (en) 2017-07-19
EP2094290A2 (en) 2009-09-02
US20100015217A1 (en) 2010-01-21
WO2008052567A3 (en) 2009-01-22
AU2007315402A1 (en) 2008-05-08
BRPI0717958A2 (pt) 2013-11-05
JP2014028839A (ja) 2014-02-13
BRPI0717958B1 (pt) 2019-12-10
BRPI0717958B8 (pt) 2021-05-25
JP6001151B2 (ja) 2016-10-05
JP2016040300A (ja) 2016-03-24
CA2668292A1 (en) 2008-05-08
AU2007315402B2 (en) 2013-05-16
MX2009004802A (es) 2009-08-12
JP2010508365A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
CA2668292C (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
US20130274171A1 (en) Trefoil factors (tff) for the treatment of chronic pulmonary diseases
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
RU2496516C2 (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
HK1135911A (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
HK1135911B (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
WO2008116470A1 (en) Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
JP7545893B2 (ja) 難治性非結核性マイコバクテリア感染症の治療のためのｇｍ－ｃｓｆ
WO2015110536A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
HK1114567B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Legal Events

Date Code Title Description
EEER Examination request